Stockscreener 앱 받기
2.45
11.36%
0.25
시간 외 거래:
2.55
0.10
+4.08%
전일 마감가:
$2.20
열려 있는:
$2.32
하루 거래량:
104.01K
Relative Volume:
0.30
시가총액:
$32.59M
수익:
$128.60K
순이익/손실:
$-4.60M
주가수익비율:
-3.8889
EPS:
-0.63
순현금흐름:
$-3.74M
1주 성능:
+8.89%
1개월 성능:
-25.76%
6개월 성능:
+249.75%
1년 성능:
+487.53%
1일 변동 폭
$2.2465
$2.49
1주일 범위
$1.94
$2.49
52주 변동 폭
$0.42
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
명칭
Nexalin Technology Inc
전화
(832) 260-0222
주소
1776 YORKTOWN, HOUSTON
NXL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
2.45 | 32.59M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
127.42 | 220.99B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.73 | 148.66B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
378.05 | 144.26B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.87 | 117.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.90 | 41.68B | 5.72B | 4.17B | 259.90M | 6.97 |
Nexalin Technology Inc 주식(NXL)의 최신 뉴스
Nexalin Technology, Inc. SEC 10-K Report - TradingView
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Corsicana Daily Sun
Nexalin Technology’s Senior VP Makes a Bold Stock Purchase - TipRanks
Nexalin technology’s Sr. VP Carolyn Shelton acquires $13,200 in stock - Investing.com India
Nexalin Technology Stock Price, Quotes and Forecasts | NASDAQ:NXL - Benzinga
Nexalin Technology, Inc. Receives USPTO Notice of Allowance for Patent on Innovative Treatment Method for Opioid and Substance Use Disorders - Nasdaq
Nexalin Technology Receives Notice of Allowance from the - GlobeNewswire
Could This Newly Patented Technology Transform How We Treat Addiction? - StockTitan
UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD - Yahoo Finance
Nexalin Technology Announces Initiation of Patient - GlobeNewswire
Nexalin Technology, Inc. Launches Clinical Trial for HALO™ Clarity Device to Treat Mild Traumatic Brain Injury and PTSD at UCSD - Nasdaq
Nexalin Technology announces initiation of patient recruitment in UCSD study - TipRanks
Can Nexalin's Brain Stimulation Technology Transform PTSD Treatment? UCSD Trial Now Recruiting Patients - StockTitan
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board - EIN News
Nexalin Technology Appoints General Wesley Clark to Military & Government Advisory Board - citybiz
Can NATO's Former Supreme Commander Help Nexalin Crack the Military Mental Health Market? - StockTitan
Nexalin Secures UCSD IRB Approval For Use Of HALO Clarity In PTSD And MTBI Clinical Studies - Nasdaq
Nexalin Technology Announces UCSD IRB Approval for use of - GlobeNewswire
Nexalin Technology Announces UCSD IRB Approval For Use Of HALO Clarity In Clinical Trials For mTBI And PTSD Treatment - Marketscreener.com
Nexalin Technology Says Halo Clarity Headset Clinical Testing Gets UCSD Institutional Review Board Approval - Marketscreener.com
Nexalin Technology, Inc. Receives IRB Approval for UCSD Clinical Trials of HALO™ Clarity Headset in Treating mTBI and PTSD - Nasdaq
Revolutionary Brain Treatment Device Enters Military PTSD Trials at UCSDPotential Breakthrough for Veterans - StockTitan
10,000 Shares in Nexalin Technology, Inc. (NASDAQ:NXL) Bought by Kingsview Wealth Management LLC - Defense World
Nexalin Technology Inc [NASDAQ: NXL] Sees Decrease in Stock Value - Knox Daily
Nexalin technology's chief medical officer buys $3,100 in shares - MSN
Nexalin Technology Inc’s latest rating changes from various analysts - Knox Daily
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition - GlobeNewswire
Nexalin Technology, Inc. Appointed Industry Co-Chair of National Traumatic Brain Injury Registry Coalition - Nasdaq
Nexalin (NXL) Secures Leadership Role in $4.5B Brain Injury MarketKey Details Investors Should See - StockTitan
Nexalin Technology announces effective registration statement - MSN
Nexalin Technology announces effective registration statement By Investing.com - Investing.com UK
Nexalin Technology Inc (NXL) Stock: A Year of Highs and Lows - The InvestChronicle
Nexalin Technology Inc (NXL) Becoming More Attractive for Investors - Knox Daily
Nexalin Technology announces publication of study of DIFS technology - MSN
Can you still get a good price for Nexalin Technology Inc (NXL) Shares at this point? - US Post News
Nexalin technology's chief medical officer buys $2,980 in common stock - MSN
Nexalin technology's chief medical officer buys $2,980 in common stock By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals launches Netherton awareness campaign - MSN
Nexalin’s Breakthrough DIFS™ Neurostimulation Device - GlobeNewswire
Nexalin Technology, Inc. Reports Landmark Study Highlights Efficacy of DIFS™ Technology in Reducing Blood Pressure in Patients with Major Depressive Disorder - Nasdaq
Clinical Trial: New Depression Therapy Achieves Dual Brain and Heart Benefits - StockTitan
Reviewing Nexeon Medsystems (OTCMKTS:NXNN) and Nexalin Technology (NASDAQ:NXL) - Defense World
NXLNexalin Technology, Inc. Latest Stock News & Market Updates - StockTitan
Nexalin technology's chief medical officer buys $4,050 in stock - MSN
Nexalin Technology Inc (NXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.34%
0.03%
자본화:
|
볼륨(24시간):